Company Diamyd Medical AB (publ) Nasdaq Stockholm

Equities

SE0005162880

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Inactive Instrument

Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.

SEK in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Products 100.0 %	0	100.0 %	1	100.0 %	+20.26%

SEK in Million	2022	Weight	2023	Weight	Delta
Sweden 100.0 %	0	100.0 %	1	100.0 %	+20.26%

Managers	Title	Age	Since
Ulf Hannelius CEO	Chief Executive Officer	49	16-04-09
Anders Essen-Möller FOU	Founder	83	95-12-31
Anna Styrud DFI	Director of Finance/CFO	63	09-12-31
Christoph Nowak CTO	Chief Tech/Sci/R&D Officer	38	20-12-31
Anton Lindqvist CTO	Chief Tech/Sci/R&D Officer	44	12-12-31
Martina Widman COO	Chief Operating Officer	43	16-08-31
Markus Jerling CTO	Chief Tech/Sci/R&D Officer	72	-
Eva Karlström LAW	General Counsel	60	20-07-31

Members of the board	Title	Age	Since
Anders Essen-Möller FOU	Founder	83	95-12-31
Erik Kjellsson Nerpin BRD	Director/Board Member	63	11-12-31
Karin Hehenberger BRD	Director/Board Member	52	21-04-27
Carl Torbjörn Bäckström BRD	Director/Board Member	76	17-03-31
Maria-Teresa Essen-Möller BRD	Director/Board Member	54	08-12-31
Mark Atkinson BRD	Director/Board Member	63	18-11-14
Karin Rosen BRD	Director/Board Member	57	23-03-09

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,741,630	0	0	72.58 %
Stock B	1	92,206,366	68,914,960 ( 74.74 %)	0

Name	Equities	%	Valuation
Bertil Lindkvist 7.592 %	7,700,000	7.592 %	8 M kr
Anders Essen-Möller 2.724 %	2,763,040	2.724 %	3 M kr
Maria-Teresa Essen-Möller 0.9504 %	963,998	0.9504 %	944 834 kr
Konstruktions o Försäljningsaktiebolaget KFAB 0.8935 %	906,250	0.8935 %	888 234 kr
Moller Jon Essen 0.3973 %	402,987	0.3973 %	394 976 kr
Moller Martin Essen 0.2943 %	298,513	0.2943 %	292 579 kr
Erika Hillborg 0.2598 %	263,537	0.2598 %	258 298 kr
Ulf Hannelius 0.2342 %	237,500	0.2342 %	232 779 kr
My Essenshaw 0.1785 %	181,002	0.1785 %	177 404 kr
Anna Styrud 0.1356 %	137,499	0.1356 %	134 766 kr

Name	Equities	%	Valuation
Anders Essen-Möller 21.76 %	556,223	21.76 %	545 165 kr
Moller Martin Essen 15.65 %	400,000	15.65 %	392 048 kr
My Essenshaw 15.65 %	400,000	15.65 %	392 048 kr
Moller Jon Essen 15.65 %	400,000	15.65 %	392 048 kr
Erika Hillborg 15.65 %	400,000	15.65 %	392 048 kr
Maria-Teresa Essen-Möller 15.65 %	400,000	15.65 %	392 048 kr

Diamyd Medical AB

Kungsgatan 29

111 56, Stockholm

+46 86 61 00 26

http://www.diamyd.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.37B
ARGENX SE	-1.80%	21.37B
BIONTECH SE	-17.75%	20.92B
GENMAB A/S	-6.91%	18.64B
WUXI APPTEC CO., LTD.	-42.00%	16.4B
BEIGENE, LTD.	-28.19%	13.53B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.28B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.85B

Bio Therapeutic Drugs